Vertex Pharmaceuticals– tag –
-
Vertex’s CRISPR Gene Therapy CASGEVY Gains Expanded FDA Approval for Sickle Cell Disease and Beta Thalassemia in Children Ages 2 and Older
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced the US FDA has approved an expanded indication for its gene therapy, CASGEVY® (exagamglogene autotemcel), for treating sickle cell disease or transfusion-dependent beta... -
HCA Healthcare Announces Promising Results for CRISPR Gene Therapy Exa-cel in Pediatric Sickle Cell Disease and Beta-Thalassemia Patients
HCA Healthcare USA Overview HCA Healthcare has announced findings from a New England Journal of Medicine study, sponsored by Vertex Pharmaceuticals, demonstrating that the CRISPR gene-editing therapy exa-cel shows promising results in pe... -
Vertex AI-Designed Candidates Hit Phase 1/2 Trials, Accelerating AI-Driven Drug Discovery
Vertex AI Search (PharmaJournalist) USA Overview Multiple AI-designed drug candidates, developed using Vertex AI Search, have advanced to Phase 1 and 2 clinical trials, firmly establishing AI as a pivotal force in pharmaceutical R&D.... -
Avaí Bio Establishes GMP-Grade Master Cell Bank for Alpha-Klotho Anti-Aging Program, Advancing Cell Therapy Toward Commercialization
PR Newswire (via USA News Group) USA Overview Avaí Bio has achieved a critical manufacturing milestone by completing its GMP-grade Master Cell Bank (MCB) for the alpha-Klotho anti-aging program. This MCB ensures a high-quality, standardi... -
Europe’s Biotech Vanguard: Ori Biotech’s Modular Automation Reshapes Cell and Gene Therapy Manufacturing
PharmTech ヨーロッパ Overview European biotechnology firms are pioneering advanced manufacturing solutions to overcome critical production hurdles in cell and gene therapies. Ori Biotech, in strategic collaborations with Cell Therapies, ... -
Health Canada Accepts Vertex Pharmaceuticals’ New Drug Submission for Suzetrigine, a Novel NaV1.8 Inhibitor, for Moderate-to-Severe Acute Pain in Adults
BioSpace (via CNW) Canada Overview Vertex Pharmaceuticals announced that Health Canada has accepted its New Drug Submission (NDS) for suzetrigine, a novel oral NaV1.8 selective pain signal inhibitor, for the treatment of moderate-to-seve... -
Vertex Pharmaceuticals Secures CASGEVY Reimbursement Agreement in Germany for Sickle Cell Disease and Beta Thalassemia
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced a reimbursement agreement in Germany for CASGEVY (exa-cel), a groundbreaking gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassem... -
iPSC-Derived Cell Therapy Pipeline 2026: From Disease Modeling to Expanding Clinical Applications
BioInformant USA Overview As of 2026, the iPSC-derived cell therapy pipeline shows rapid advancements in disease modeling and drug discovery, though broad clinical use in human patients still faces challenges. iPSC-derived cells hold imm... -
Vertex’s Zimislecel Cell Therapy Achieves Insulin Independence in 10 of 12 Type 1 Diabetes Patients
Breakthrough T1D Australia Overview Vertex Pharmaceuticals announced highly promising results from its FORWARD-101 trial of Zimislecel (formerly VX-880), an iPSC-derived cell therapy for Type 1 Diabetes (T1D). Ten of 12 participants achi...
